USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: AMUNIX, INC.
Address: 500 Ellis Street, Suite B
MOUNTAIN VIEW, CA 94043-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $366,097.00 3
SBIR Phase II $2,006,049.00 2

Award List:

Drug binding microprotein domains for targeted delivery of cytotoxic drugs

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Volker Schellenberger
Award Amount: $108,284.00
Abstract:
DESCRIPTION (provided by applicant): Targeted delivery of cytotoxic drugs to tumor tissues is an effective strategy to minimize drug exposure of normal tissues and thus improve the toxicity and efficacy profiles of these agents. A tumor targeting system co nsists of a tumor recognition moiety linked… More

Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Volker Schellenberger
Award Amount: $100,263.00
Abstract:
DESCRIPTION (provided by applicant): Protein drugs have been approved for many therapeutic indications and represent a rapidly growing segment of the pharmaceutical industry. However, many approved protein drugs and candidates in development fail to reach their potential efficacy due to suboptimal… More

Targeting toxins to tumors using microproteins

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Volker Schellenberger
Award Amount: $995,124.00
Abstract:
DESCRIPTION (provided by applicant): Treatment of metastatic tumors is a major health challenge. Recently, antibody-based therapies have been developed that are more specific and have fewer side effects compared with conventional chemotherapy. However, the potency of most antibody therapeutics is… More

Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Volker Schellenberger
Award Amount: $1,010,925.00
Abstract:
DESCRIPTION (provided by applicant): The market for protein-based biopharmaceuticals is rapidly expanding. However, the clinical utility of many proteins is limited by their short serum half-life, requiring frequent injections. The most common approach to improve serum half-life is PEGylation. The… More

XTENylation of enfuvirtide to generate a bio-better product with improved dosing

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Volker Schellenberger – 408-540-8129
Award Amount: $157,550.00
Abstract:
DESCRIPTION (provided by applicant): Enfuvirtide (Fuzeon, T-20) is a peptide HIV entry inhibitor currently dosed twice daily by subcutaneous injection. While proven to be efficacious and safe, enfuvirtide is under-utilized due to its frequent dosing, cumbersome administration, and inducement of… More